Article
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
Journal of hepatology - 1 Aug 2015
Lalezari Jacob, Sullivan J Greg, Varunok Peter, Galen Edward, Kowdley Kris V, Rustgi Vinod, Aguilar Humberto, Felizarta Franco, McGovern Barbara, King Martin, Polepally Akshanth R, Cohen Daniel E
Abstract excerpt
BACKGROUND & AIMS: Hepatitis C virus (HCV)-infected patients with a history of injection drug use have low rates of initiation and completion of interferon-based therapies. This study evaluated efficacy, safety, and pharmacokinetics of a 12-week all-oral regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir+ribavirin in HCV genotype 1-infected patients on stable opioid replacement therapy. METHODS: This was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.